Loading
The enzyme that cuts both DNA strands to untangle chromosomes before cell division. Etoposide and the anthracyclines hold it in the cut state, filling dividing cells with double-strand breaks. This dossier gathers the 6 products (0 approved), 15 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Type IIA topoisomerase, proliferation-associated isoform; poisoned by etoposide and anthracyclines into a stable cleavage complex.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| HER2-positive breast cancer | about 35% | TOP2A co-amplification with HER2, FISH, 4,943 breast cancers analysed | Co-amplified tumours gained most from anthracycline-containing chemotherapy | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Phase 3 | Withdrawn or failed |
|---|---|---|
| Small molecule 4 | - | |
| Albumin-binding small-molecule prodrug of doxorubicin, intravenous 1 | - | |
| Chemotherapy 1 | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
DeLLphi-304 NCT05740566 | 3 | Positive | Second-line small-cell lung cancer: tarlatamab vs chemotherapy | OS HR 0.60. | |
| 3 | Recruiting | A Multicenter, Randomized, Open-label Phase III Clinical Study of Intravesical SHR-1501 Combined With Bacillus Calmette Guerin (BCG) Versus Investigator-selected Chemotherapy In Patients With BCG-unresponsive Papillary-Only Non-muscle-invasive Bladder Cancer (NMIBC) (NiBladder 1) | - | ||
| 3 | Negative | Metastatic, locally advanced or unresectable soft tissue sarcoma after at least one prior systemic therapy, randomised against investigator's choice of dacarbazine, pazopanib, gemcitabine with docetaxel, doxorubicin or ifosfamide; started January 2014 | - | ||
| 3 | Completed | Medical Research Council Working Party on Leukaemia in Childhood Acute Myeloid Leukaemia Trial 12 | - | ||
| 3 | Completed | RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) | - | ||
| 3 | - | ACUTE MYELOID LEUKAEMIA TRIAL 12 | - | ||
IDeate-Lung02 NCT06203210 | 3 | Recruiting | Relapsed SCLC after one prior line: ifinatamab deruxtecan vs topotecan, amrubicin, or lurbinectedin | - | |
| 3 | Recruiting | A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC) | - | ||
| 2 | Completed | A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | - | ||
| 2 | Completed | Randomized Phase II Study of Two Doses of Pixantrone in Patients With Metastatic Breast Cancer | - | ||
| 2 | Recruiting | A Multicenter, Randomised, Open-label Phase II Study to Evaluate the Efficacy and Safety of Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Platinum-based Neoadjuvant Chemotherapy | - | ||
| 2 | Active | Open-label, Randomized, Comparative Phase 2 Study of Combination Immunotherapy Plus Standard-of-care Chemotherapy Versus Standard-of-care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | - | ||
| 2 | Completed | A Multicentre, Phase II, Open Label, Single Arm Study of Pixantrone in Patients With CD20-positive Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma Treated With Rituximab, Ifosfamide and Etoposide. | - | ||
| 2 | Recruiting | Comparison of Teniposide, Cisplatin and Serplulimab Regimen With Etoposide, Cisplatin and Serplulimab Regimen for Treatment of Extensive Stage Small Lung Cancer, a Random, Open Label, Positive Control, Multicenter Study | - | ||
| 2 | Recruiting | A Single-center, Single-arm, Open-label Study of the Combination of Teniposide Injection and Cisplatin in the Treatment of Newly Diagnosed Patients With Central Malignant Germ Cell Tumors. | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"Topoisomerase II alpha" OR ABSTRACT:"Topoisomerase II alpha" OR TITLE:"TOP2A" OR ABSTRACT:"TOP2A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Topoisomerase II alpha (TOP2A), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/top2a.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/top2a.json. Licence CC BY-NC 4.0.